Laboratory of Aging and Neurodegeneration

We examine the role of APOE in Alzheimer's disease. APOE is the strongest genetic risk factor for Alzheimer's disease, and we are trying to understand how it affects that risk. APOE is important for normal cholesterol trafficking in the body, so we examine how cholesterol-related molecules are involved in Alzheimer's disease pathogenesis. APOE also affects glial inflammation, and we are testing ways to alter apoE expression. We also examine how normal aging affects these systems. We conduct various preclinical studies to look at therapeutic approaches using anti-inflammatory drugs, cholesterol lowering agents, and neurotrophic compounds. On a molecular level, we examine how receptors for apoE affect cellular signaling and processes such as synapse formation and glial inflammation. The model systems that we use are established cell cultures, primary neurons and glia, transgenic mice that express the different APOE isoforms, viral expression vectors, and human brain samples.

G. William Rebeck, Ph.D.
Professor, Department of Neuroscience
Georgetown University Medical Center

Grant Funding:

NIH R01 AG035379-01 (co-PI Rebeck GW, Weeber EJ), "ApoE effects on neuron signaling and function via ApoER2" 9/1/2010 to 8/31/2015

NIH F31 1F31AG051308-01 (DiBattista, AM), "Effect of ibuprofen and Alzheimer's risk genotype, APOE, on brain structure and function in mice" 7/1/2015 to 6/30/2016

ApoE PPG Symposium:

Every year, an ApoE symposium is held in the first week of June. This year, the symposium will be on "ApoE, ApoE Receptors, and Neurodegeneration." For more information and to register: click here